U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H21F3N4O4
Molecular Weight 510.4655
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALTIRATINIB

SMILES

C1CC1C(=Nc2cc(ccn2)Oc3cc(c(cc3F)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F)F)O

InChI

InChIKey=GNNDEPIMDAZHRQ-UHFFFAOYSA-N
InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)

HIDE SMILES / InChI

Molecular Formula C26H21F3N4O4
Molecular Weight 510.4655
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Altiratinib, a novel c-MET/TIE-2/VEGFR inhibitor, was able to effectively reduce tumor burden in vivo and block c-MET signaling, cell growth and migration. Altiratinib inhibits not only mechanisms of tumor initiation and progression, but also drug resistance mechanisms in the tumor and microenvironment. Altiratinib durably inhibits MET, both wild-type and mutated forms, in vitro and in vivo. Altiratinib exhibits properties amenable to oral administration and exhibits substantial blood-brain barrier penetration, an attribute of significance for eventual treatment of brain cancers and brain metastases. It is currently in Phase 1 clinical development for the treatment of solid tumors.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 4.6109 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
2015 Jan 8
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
2015 Sep
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
2016 Sep
Patents

Patents

Sample Use Guides

In escalating dose (starting dose 15 mg) twice daily every 12 hours for a 28-day cycle
Route of Administration: Oral
EBC-1 (NSCLC) and MKN-45 (gastric cancer) human cancer cell lines genomically amplify and overexpress MET with subsequent ligand-independent MET activation. Altiratinib inhibited MET phosphorylation with IC50 values of 0.85 nmol/L and 2.2 nM/L, respectively. In the U-87 glioblastoma cell line, MET and HGF are both expressed. Altiratinib blocked autocrine activation of MET phosphorylation in these cells (IC50 of 6.2 nM/L).
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:37:15 UTC 2021
Edited
by admin
on Sat Jun 26 12:37:15 UTC 2021
Record UNII
T678746713
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALTIRATINIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
DP-5164
Code English
ALTIRATINIB [USAN]
Common Name English
1,1-CYCLOPROPANEDICARBOXAMIDE, N-(4-((2-((CYCLOPROPYLCARBONYL)AMINO)-4-PYRIDINYL)OXY)-2,5-DIFLUOROPHENYL)-N'-(4-FLUOROPHENYL)-
Systematic Name English
ALTIRATINIB [WHO-DD]
Common Name English
N-(4-((2-((CYCLOPROPYLCARBONYL)AMINO)PYRIDIN-4-YL)OXY)-2,5-DIFLUOROPHENYI)-N-(4- FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
Systematic Name English
DCC-2701
Code English
ALTIRATINIB [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 441714
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
NCI_THESAURUS C1967
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
NCI_THESAURUS C1742
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
Code System Code Type Description
CAS
1345847-93-9
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL3545365
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
PRIMARY
NCI_THESAURUS
C118290
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
PRIMARY
FDA UNII
T678746713
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
PRIMARY
PUBCHEM
54576299
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
PRIMARY
INN
10100
Created by admin on Sat Jun 26 12:37:15 UTC 2021 , Edited by admin on Sat Jun 26 12:37:15 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY